Decibel Therapeutics Appoints Dr. Elisabeth Leiderman as Chief Financial Officer

BOSTON--(BUSINESS WIRE)--Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced the appointment of Elisabeth Leiderman, M.D., MBA, as Chief Financial Officer.

“Elisabeth brings more than 15 years of business development, strategy and finance experience in the life sciences industry to our team at Decibel. She joins us at an important time as we build Decibel to advance our pipeline of restorative and regenerative medicines,” said Laurence Reid, Ph.D., Chief Executive Officer of Decibel. “We are thrilled to welcome Elisabeth to Decibel; she will lead our financing strategy and corporate development as we work to develop the first approved therapies that restore hearing and balance.”

Dr. Leiderman has extensive expertise in the biotech sector related to financings, initial public offerings, mergers and acquisitions, and licensing transactions. Before joining Decibel, she served as Chief Business Officer for Complexa, Inc., a clinical stage biopharmaceutical company focused on life-threatening fibrosis and inflammatory diseases. Prior to Complexa, Dr. Leiderman was Senior Vice President, Head of Corporate Development at Fortress Biotech, where she was responsible for key business growth initiatives, including business development, strategy, financial analysis and capital raising. Earlier in her career, Dr. Leiderman developed her investment expertise at banking groups Nomura, Credit Suisse, Jefferies and UBS. She began her career in medical affairs at AstraZeneca, where she analyzed product and industry trends related to the central nervous system. Dr. Leiderman earned an M.D. from the Sackler School of Medicine at Tel Aviv University, an MBA from The Wharton School at the University of Pennsylvania and a B.A. from The University of Pennsylvania.

“This is a time of increasing interest in the field of hearing and balance therapeutics, and I am excited to be joining Decibel as the company advances its pipeline of gene therapies that target the inner ear,” said Dr. Leiderman. “I look forward to working with this tenacious team of drug hunters as we advance our therapies through clinical studies, with the goal of developing the first approved therapies to treat hearing loss and balance problems.”

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company focused on developing treatments that restore functional hair cells within the inner ear to treat disorders of hearing and balance. Leveraging industry-leading single-cell genomics capabilities and proprietary gene therapy technologies, Decibel has established the world’s first comprehensive research, discovery and drug development platform aimed at restoring hearing and balance function. Decibel’s pipeline, including its lead gene therapy program (DB-OTO) to treat congenital monogenic deafness and its ototoxicity prevention program, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow @DecibelTx.